Table 1 Basic characteristics of patients with ART. Pa, comparisons among three groups. Pb, comparison between ART and planned pregnancy. Pc, comparison between ART and unplanned pregnancy. Pd, comparison between planned and unplanned pregnancy
ART (n = 66) | Planned (n = 214) | Unplanned (n = 66) | Pa | Pb | Pc | Pd | |
|---|---|---|---|---|---|---|---|
Basic characteristics | |||||||
Age, mean ± SD | 34.0 ± 3.8 | 31.3 ± 4.3 | 28.4 ± 5.1 | < 0.001 | < 0.001 | < 0.001 | < 0.001 |
Pre-pregnant BMI, kg/m2, mean ± SD | 21.4 ± 2.3 | 20.4 ± 2.7 | 21.2 ± 2.3 | 0.006 | 0.007 | 0.618 | 0.030 |
Disease course, months, median (IQR) | 42.5 (25, 84.8) | 72 (41, 108) | 33.5 (10.5, 63) | < 0.001 | < 0.001 | < 0.001 | < 0.001 |
Primipara, n (%) | 43 (65.2) | 152 (71.0) | 35 (53.0) | 0.025 | 0.444 | 0.215 | 0.008 |
Previous pregnancies, mean ± SD | 2.6 ± 1.6 | 2.1 ± 1.2 | 2.0 ± 1.3 | 0.012 | 0.007 | 0.020 | 0.562 |
Obstetrical history | |||||||
Incidence rate, n (%) | 27 (40.9) | 68 (31.8) | 10 (15.2) | 0.004 | 0.183 | 0.002 | 0.011 |
Spontaneous abortion, n (%) | 17 (25.8) | 33 (15.4) | 5 (7.6) | 0.016 | 0.066 | 0.009 | 0.148 |
Ectopic pregnancy, n (%) | 11 (16.7) | 4 (1.9) | 0 (0) | < 0.001 | < 0.001 | 0.001 | 0.576 |
Therapeutic abortion, n (%) | 7 (10.6) | 19 (8.9) | 3 (4.5) | 0.424 | |||
Preeclampsia/eclampsia, n (%) | 1 (1.5) | 4 (1.9) | 0 (0) | 0.825 | |||
Stillbirth, n (%) | 0 (0) | 9 (4.2) | 1 (1.5) | 0.138 | |||
Premature delivery, n (%) | 0 (0) | 8 (3.7) | 2 (3.0) | 0.277 | |||
Neonatal death, n (%) | 0 (0) | 2 (0.9) | 0 (0) | 1.000 | |||
Laboratory test | |||||||
ANA, n (%) | 59 (89.4) | 187 (87.4) | 64 (97.0) | 0.088 | |||
Anti-dsDNA, n (%) | 15 (22.7) | 114 (53.3) | 48 (72.7) | < 0.001 | < 0.001 | < 0.001 | 0.007 |
Anti-SSA, n (%) | 16 (24.2) | 93 (43.5) | 41 (62.1) | < 0.001 | 0.006 | < 0.001 | 0.011 |
Anti-SSB, n (%) | 8 (12.1) | 20 (9.3) | 11 (16.7) | 0.262 | |||
aCL-IgG, n (%) | 2 (3.0) | 10 (4.7) | 3 (4.5) | 0.933 | |||
aCL-IgM, n (%) | 0 (0) | 3 (1.4) | 4 (6.1) | 0.058 | |||
β2-GPI-IgG, n (%) | 2 (3.0) | 3 (1.4) | 2 (3.0) | 0.356 | |||
β2-GPI-IgM, n (%) | 3 (4.5) | 0 (0) | 1 (1.5) | 0.013 | |||
LA, n (%) | 1 (1.5) | 4 (1.9) | 3 (4.5) | 0.473 | |||
Pre-pregnant treatment | |||||||
Glucocorticoids, n (%) | 26 (39.4) | 200 (93.5) | 26 (39.4) | < 0.001 | < 0.001 | 1.000 | < 0.001 |
Immunosuppressants, n (%) | 4 (6.1) | 38 (17.8) | 8 (12.1) | 0.055 | 0.028 | 0.365 | 0.344 |
CsA, n (%) | 4 (6.1) | 22 (10.3) | 4 (6.1) | 0.295 | |||
TAC, n (%) | 0 (0) | 7 (3.3) | 1 (1.5) | 0.371 | |||
AZA, n (%) | 0 (0) | 9 (4.2) | 0 (0) | 0.050 | |||
HCQ, n (%) | 57 (86.4) | 176 (82.2) | 20 (30.3) | < 0.001 | 0.461 | 0.461 | < 0.001 |
LDA, n (%) | 10 (15.2) | 35 (16.4) | 1 (1.5) | 0.007 | 0.852 | 0.009 | 0.003 |
LMWH, n (%) | 7 (10.6) | 11 (5.1) | 0 (0) | 0.014 | 0.148 | 0.013 | 0.072 |